Skip to main content
Fig. 4 | Journal for ImmunoTherapy of Cancer

Fig. 4

From: Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

Fig. 4

IT administration of MEDI9197 induces lymphoid aggregates in the tumor. a Gross histological changes to tumors dosed with MEDI9197 were evaluated in H&E stained tissue sections. Eight days after B16-OVA tumors were implanted SC into C57BL/6 J albino mice (3/group), a single dose of 20 μg MEDI9197 or Vehicle was administered IT. Some mice were untreated (Naïve, n = 3). After 1- and 7-days post-dose, FFPE tumors were sectioned, H&E stained, and scored for lymphoid aggregates. Each tumor photomicrograph is from one mouse and is representative of each treatment group. Data is representative of 3 independent experiments in the B16-OVA model. b Number of lymphoid aggregates per section for each mouse from each group is shown 1- and 7-days post-dose. Statistical analysis was performed by two-way ANOVA with Tukey’s post hoc test. ***p = 0.001, ****p < 0.001

Back to article page